RxDoctor Payments Data

Vanna Gold

Family Medicine · Lampasas, TXNPI 1669818910

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations.

$1,527in general payments, 2019–2025

Across 105 payments — averaging $14.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$247
  • Biohaven Pharmaceuticals, Inc.$167
  • AstraZeneca$162
  • GSK$139
  • AbbVie$128
  • Amgen$72
  • plus $612 from 20 others
$3,340,895in research payments, 2019–2025

Across 1,151 payments — averaging $2902.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Applied Therapeutics, Inc.$900K
  • AbbVie$416K
  • GSK$340K
  • Sanofi US Services Inc.$314K
  • Merck$310K
  • Genentech, Inc.$210K
  • plus $852K from 11 others

What the payments were for

  • Food & beverage$1,527100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,527 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$10,593
Mirtazapine23$1,469
Amiodarone Hcl15$1,233
Losartan Potassium55$1,166
Duloxetine Hcl35$1,124
Metoprolol Succinate28$630
Levothyroxine Sodium42$621
Gabapentin35$394
Atorvastatin Calcium45$379
Famotidine42$307
Buspirone Hcl16$267
Amoxicillin12$249
Latanoprost15$214
Ondansetron Hcl19$210
Furosemide18$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$50$10,59331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lampasas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →